--- title: New Biosimilar Insulin Study Published description: Learn more about biosimilar insulin and Profil's expertise in the field. We have just published a new study and list all available resources. image: https://blog.profil.com/hubfs/BLUE_MOON/Header/Header_1077x260px_About_Profil.jpg --- [![profil-logo-wortbild-with claim-4c-offset_1000px](https://blog.profil.com/hs-fs/hubfs/profil-logo-wortbild-with%20claim-4c-offset_1000px.png?width=250&name=profil-logo-wortbild-with%20claim-4c-offset_1000px.png "profil-logo-wortbild-with claim-4c-offset_1000px")](https://www.profil.com) [![Contact](https://no-cache.hubspot.com/cta/default/481167/1f89c7d1-107f-4c8d-aa7b-f85d0dce14da.png)](https://cta-redirect.hubspot.com/cta/redirect/481167/1f89c7d1-107f-4c8d-aa7b-f85d0dce14da) [Patient information](https://www.profil.de) ![Header_1077x260px_About_Profil.jpg](https://blog.profil.com/hs-fs/hubfs/BLUE_MOON/Header/Header_1077x260px_About_Profil.jpg?width=1077&name=Header_1077x260px_About_Profil.jpg "Header_1077x260px_About_Profil.jpg") # New Biosimilar Insulin Study Published ![Dr.](https://blog.profil.com/hubfs/BLUE_MOON/content-bilder/Mitarbeiter/Events_Mitarbeiter.png) Posted by [Dr. Lars Bochmann](https://blog.profil.com/blog/author/dr-lars-bochmann) on Mar 2, 2017 5:01:00 PM ![Two clicks for more privacy: The linkedin Share button will be enabled once you click here. Activating the button already sends data to linkedin.](https://cdn2.hubspot.net/hub/3825816/hubfs/BM/IN.png?width=20&name=IN.png "Two clicks for more privacy: The linkedin Share button will be enabled once you click here. Activating the button already sends data to linkedin.") ![Two clicks for more privacy: The Twitter Share button will be enabled once you click here. Activating the button already sends data to Twitter.](https://blog.profil.com/hubfs/BLUE_MOON/twitter.png "Two clicks for more privacy: The Twitter Share button will be enabled once you click here. Activating the button already sends data to Twitter.") ### Profil is an expert on biosimilar insulins In the past Profil has worked on biosimilar insulins a lot. We are the leading provider of bioequivalence trials for these insulins and with our next generation glucose clamp technology, ClampArt, we offer several advantages for carrying out such trials. Especially for fast acting insulins the advantages of using automated glucose clamping become apparent and easy to understand. With the much better time-resolution, important time points can get resolved better and results are more reliable.  See the many resources below to learn more about biosimilar insulins and Profil capabilities: - [On-demand online seminar on biosimilar insulins ](https://info.profil.com/webinar-on-demand-biosimilars) - [Blog post on biosimilar insulins](https://blog.profil.com/blog/clinical-trials-for-insulin-biosimilars) - [Our website dedicated to the topic](https://www.profil.com/services/biosimilar) - [Download a recent conference poster on biosimilars](https://info.profil.com/download-profil-conference-posters) You see, Profil is the expert when it comes to the topic of insulin biosimilars. ### Peer reviewed biosimilar insulin study published We are proud to be adding to the array of resources available on this topic. In February we published a peer reviewed paper in the journal "Diabetes, Obesity and Metabolism". You can get the paper [here](http://onlinelibrary.wiley.com/doi/10.1111/dom.12856/abstract). In this study we compared the pharmacokinetics (PK) and pharmacodynamics (PD) of 3 rapid-acting insulin lispro products. These were SAR342434 solution, United States (US)-approved Humalog and European Union (EU)-approved Humalog. Check out this paper to see how to design such a bioequivalence trial.  If this topic is interesting to you, then register for our blog and don't miss future news. We are going to publish soon an analysis of the new American guidelines for biosimilars. This will certainly stir up the regulatory landscape and maybe the developmental plans for many biosimilar companies.  Also, you may be interested in [our online seminar on biosimilar insulin development](https://info.profil.com/webinar-on-demand-biosimilars). Watch this interesting and free session to learn how to comply with the EU guidelines on biosimilar insulin development. Topics: [Clinical Trials in Diabetes](https://blog.profil.com/blog/topic/clinical-trials-in-diabetes) [Leave a comment](https://blog.profil.com/blog/biosimilar-insulin#comment_form) ### Subscribe to Email Updates ### Our most popular Posts ### Posts by Topic - [Clinical Trials in Diabetes (127)](https://blog.profil.com/blog/topic/clinical-trials-in-diabetes) - [About Profil (69)](https://blog.profil.com/blog/topic/about-profil) - [Clinical Trial Methods (68)](https://blog.profil.com/blog/topic/clinical-trial-methods) - [The Science behind Diabetes (64)](https://blog.profil.com/blog/topic/the-science-behind-diabetes) - [Treating Diabetes (62)](https://blog.profil.com/blog/topic/treating-diabetes) - [Diabetes Technology (41)](https://blog.profil.com/blog/topic/diabetes-technology) - [Clinical trials in Obesity (11)](https://blog.profil.com/blog/topic/clinical-trials-in-obesity) - [Events (4)](https://blog.profil.com/blog/topic/events) - [CRO selection (2)](https://blog.profil.com/blog/topic/cro-selection) - [Regulatory Affairs (2)](https://blog.profil.com/blog/topic/regulatory-affairs) [see all](https://blog.profil.com/blog/biosimilar-insulin#) ## You might also like this post ### ["What are glucose clamps and why do we need them?"](https://blog.profil.com/blog/what-are-glucose-clamps-and-why-do-we-need-them)